



COPY OF PAPERS  
ORIGINALLY FILED

Attorney's Docket No. 5470.148CX2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Baldwin et al.  
Serial No.: 08/959,160  
Filed: 28 October 1997  
For: **Use of NF- $\kappa$ B Inhibition in  
Combination Therapy for Cancer**

Examiner: T. McKelvey

Group Art Unit: 1636

March 7, 2002

Commissioner for Patents  
Washington, DC 20231

#25B  
3da  
3-2802  
**RECEIVED**  
MAR 22 2002  
TECH CENTER 1600/2900

**RESPONSE AND AMENDMENT**

Sir:

This is in response to the Official Action of 7 September 2001.

**In the Claims**

Please enter the following amended claims:

BC  
1. (twice amended) A method of enhancing the cytotoxic effects of an antineoplastic chemotherapeutic agent, comprising transiently administering to a mammalian subject in need of such therapy a therapeutically effective amount of an NF- $\kappa$ B inhibitor in conjunction with the administration of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of said NF- $\kappa$ B inhibitor.

B2  
C3  
6. (twice amended) A method of enhancing chemotherapeutic cytotoxicity in a mammalian subject treated with an antineoplastic chemotherapeutic agent, comprising transiently administering to the mammalian subject a therapeutically effective amount of an NF- $\kappa$ B inhibitor in conjunction with the administration of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of said NF- $\kappa$ B inhibitor.